
    
      To assess the bioequivalence of Vidaza® and Luitpold Azacitidine pharmacokinetics, in terms
      of Cmax, AUC0-t and AUC0-∞, following SC administration.

      To assess the comparative safety of Vidaza® versus Luitpold Azacitidine during the 2 day
      study period.
    
  